Laura Shawver, Director at ARS Pharmaceuticals, Inc. (SPRY), sold 200,000 shares at $6.80 ($1.4M) on 2023-06-01, disclosed to the SEC on 2023-06-02.
Scheduled sale ($1.4M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.80 | 73,059 | $497K | 36.3% |
| 2 | $6.80 | 73,059 | $497K | 36.3% |
| 3 | $6.95 | 26,941 | $187K | 13.7% |
| 4 | $6.95 | 26,941 | $187K | 13.7% |
| Total | $6.84 avg | 200,000 | $1.4M | 100% |
| Filing → |
| SPRY | SELL | 2025-02-04 | $616K | — | Filing → |
| SPRY | SELL | 2025-01-07 | $555K | — | Filing → |
| SPRY | SELL | 2024-12-04 | $5.2M | — | Filing → |